Abstract:Indoleamine 2,3-Dioxygenase (IDO), is a speed limiting enzyme that catalyzes the decomposition and metabolism of Tryptophan along Tryptophan-IDO-Kynurenine pathway [1]. Tryptophan is a necessary amino acid for activating cell growth and metabolism. Additionally, the insufficiency of Tryptophan can lead to immune system dysfunction. Raising the level of Indoleamine 2,3-Dioxygenase protein can promote stagnation and apoptosis of effector T cells [2].In contrast, the decline in the number of effect T cells naturally protects cancer cells from attack. Therefore, Indoleamine 2,3-Dioxygenase is a potential target for tumour immunotherapy, such as melanoma, ovarian cancer, lung cancer, leukaemia, and so on, especially in solid tumours [3]. In the study, we have done sets of virtual screening aided by computer techniques in order to find potentially effective inhibitors of Indoleamine 2,3-Dioxygenase. Firstly, screening based on structure was carried out by Libdock. Then, ADME (adsorption, distribution, metabolism, excretion) and toxicity prediction were also analyzed. Molecular docking and 3D-QSAR pharmacophore generation were used to study the mechanism of these compounds and Indoleamine 2,3-Dioxygenase's binding. A molecular dynamic analysis was carried out to assess if these potential compound's binding is stable enough. According to the results of the analysis above, two potential compounds (ZINC000012495022 and ZINC000003791817) from the ZINC database were discovered to interact with Indoleamine 2,3-Dioxygenase with appropriate energy and proved to be none toxic. The study offered valuable information of Indoleamine 2,3-Dioxygenase inhibitor-based drug discovery in cancer therapy by increasing the activity of T cells and releasing immunity suppression [4, 5].

Indoleamine 2, 3-Dioxygenase 1 Inhibitory Compounds from Natural Sources

Research Progress of Indoleamine 2,3-Dioxygenase Inhibitors

Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO-1) Inhibitors Based on Ortho-Naphthaquinone-Containing Natural Product

Design, Synthesis and Biological Evaluation of Novel Naphthoquinone Derivatives As IDO1 Inhibitors

Discovery and Preliminary Structure-Activity Relationship of 1H-Indazoles with Promising Indoleamine-2,3-Dioxygenase 1 (ido1) Inhibition Properties

Design, Synthesis and Structure-Activity Relationship Study of Novel Naphthoindolizine and Indolizinoquinoline-5,12-dione Derivatives As IDO1 Inhibitors

Advances in Indoleamine 2, 3-Dioxygenase 1 Inhibitors

Recent Advances of IDO Inhibitors

Computational study on new natural compound inhibitors of indoleamine 2,3-dioxygenase 1

Inhibition Mechanism of Indoleamine 2, 3-Dioxygenase 1 (IDO1) by Amidoxime Derivatives and Its Revelation in Drug Design: Comparative Molecular Dynamics Simulations

Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy

Discovery, synthesis and biological evaluation of novel isoquinoline derivatives as potent indoleamine 2, 3-dioxygenase 1 and tryptophan 2, 3-dioxygenase dual inhibitors

Discovery of Novel Inhibitors of Indoleamine 2,3-Dioxygenase 1 Through Structure-Based Virtual Screening

Heme-containing Enzymes and Inhibitors for Tryptophan Metabolism

Discovery of 1-(Hetero)aryl-β-carboline Derivatives As IDO1/TDO Dual Inhibitors with Antidepressant Activity.

Research of the new indoleamine 2,3-dioxygenase inhibitors and its treatment of human diseases

Indoleamine 2,3-Dioxygenase (IDO) Activity: A Perspective Biomarker for Laboratory Determination in Tumor Immunotherapy

Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor

Identification and Preliminary Structure–activity Relationships of 1-Indanone Derivatives As Novel Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors

Discovery of novel IDO1 inhibitors via structure-based virtual screening and biological assays

Development of Indoleamine 2,3-Dioxygenase 1 Inhibitors for Cancer Therapy and Beyond: A Recent Perspective